Dendritic nanoconjugates for intracellular delivery of neutral oligonucleotides
Source abstract
Abstract
Dendrimer-based gene delivery has been constrained by intrinsic toxicity and suboptimal nanostructure. Conjugation of neutral morpholino oligonucleotides (ONs) with PAMAM dendrimers resulted in neutral, uniform, and ultra-small (∼10 nm) nanoconjugates. The nanoconjugates dramatically enhanced cellular delivery of the ONs in cancer cells. After release from the dendrimer in the cytosol, the ONs produced potent functional activity without causing significant cytotoxicity. When carrying an apoptosis-promoting ON, the nanoconjugates produced cancer cell killing directly. Thus, the dendritic nanoconjugates may provide an effective tool for delivering ONs to tumors and other diseased tissues.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Molecular Pharmaceutics
UNC Eshelman School of Pharmacy
University of North Carolina
Chapel Hill, USA
Clinical Research Center
State Key Laboratory of Pharmaceutical Biotechnology
Department of Radiation Oncology
Lineberger Comprehensive Cancer Center
Funding
National Cancer Institute
References (24)
Show source-provided references
1. Bennett · Annu. Rev. Pharmacol. Toxicol. · 2010 · 50 · 25910.1146/annurev.pharmtox.010909.105654 ↗
2. Wahlestedt · Nat. Rev. · 2013 · 12 · 433
3. Kole · Nat. Rev. · 2012 · 11 · 125
4. Cirak · Lancet · 2011 · 378 · 59510.1016/S0140-6736(11)60756-3 ↗
5. Ming · Expert Opin. Drug Delivery · 2011 · 8 · 43510.1517/17425247.2011.561313 ↗
6. Shcharbin · Expert Opin. Drug Delivery · 2013 · 10 · 168710.1517/17425247.2013.853661 ↗
7. Dutta · Nanomedicine · 2010 · 6 · 2510.1016/j.nano.2009.05.005 ↗
8. Jain · Int. J. Pharm. · 2010 · 394 · 12210.1016/j.ijpharm.2010.04.027 ↗
9. Summerton · Antisense Nucleic Acid Drug Dev. · 1997 · 7 · 18710.1089/oli.1.1997.7.187 ↗
10. Amantana · Curr. Opin. Pharmacol. · 2005 · 5 · 55010.1016/j.coph.2005.07.001 ↗
11. Ming · Biomaterials · 2013 · 34 · 793910.1016/j.biomaterials.2013.06.066 ↗
12. Shieh · J. Invest. Dermatol. · 2009 · 129 · 249710.1038/jid.2009.83 ↗
13. Yoo · Nucleic Acids Res. · 2000 · 28 · 422510.1093/nar/28.21.4225 ↗
14. Yoo · Pharm. Res. · 1999 · 16 · 179910.1023/A:1018926605871 ↗
15. Kumar · Mol. Ther. Nucl. Acids · 2014 · 3 · e21010.1038/mtna.2014.61 ↗
16. Deneke · Curr. Top. Cell. Regul. · 2000 · 36 · 15110.1016/S0070-2137(01)80007-8 ↗
17. Hussain · J. Controlled Release · 2004 · 99 · 13910.1016/j.jconrel.2004.06.009 ↗
18. Ivanov · Methods Mol. Biol. · 2014 · 1174 · 310.1007/978-1-4939-0944-5_1 ↗
19. Schwartz · J. Cell Sci. · 2008 · 121 · 24610.1242/jcs.03495 ↗
20. Howe · Proc. Natl. Acad. Sci. U. S. A. · 1988 · 85 · 757710.1073/pnas.85.20.7577 ↗
21. Ming · Mol. Pharm. · 2012 · 9 · 150210.1021/mp300113c ↗
22. Ming · J. Controlled Release · 2011 · 153 · 8310.1016/j.jconrel.2011.04.029 ↗
23. Bauman · Nucleic Acids Res. · 2010 · 38 · 834810.1093/nar/gkq731 ↗
24. Zammarchi · Proc. Natl. Acad. Sci. U. S. A. · 2011 · 108 · 1777910.1073/pnas.1108482108 ↗